Docket of HB513

Docket Abbreviations

Bill Title: relative to affordability and safety of clinician administered drugs.

Official Docket of HB513:
Date Body Description
01/11/2023 House Introduced (opens in new window) (in recess of) 01/05/2023 and referred to Commerce and Consumer Affairs HJ 3 P. 19
02/03/2023 House ==CANCELLED== Public Hearing: 02/07/2023 02:15 pm LOB 210-211
02/09/2023 House Public Hearing: 02/15/2023 02:00 pm LOB 302-304
02/23/2023 House Subcommittee Work Session: 03/08/2023 10:00 am LOB 302-304
02/23/2023 House Executive Session: 03/08/2023 01:15 pm LOB 302-304
03/08/2023 House Executive Session: 03/15/2023 11:00 am LOB 302-304
03/08/2023 House Subcommittee Work Session: 03/15/2023 10:05 am LOB 302-304
03/15/2023 House Retained in Committee
08/30/2023 House ==CANCELLED== Subcommittee Work Session: 09/06/2023 01:15 pm LOB 302-304
09/06/2023 House ==RESCHEDULED== Subcommittee Work Session: 09/20/2023 01:15 pm LOB 302-304 HC 36
10/17/2023 House ==RECESSED== Executive Session: 11/08/2023 01:30 pm LOB 302-304 HC 42
11/08/2023 House ==CANCELLED== Executive Session: 11/15/2023 11:00 am LOB 302-304 HC 42
11/16/2023 House Committee Report: Refer for Interim Study 11/08/2023 (Vote 19-0; CC) HC 49 P. 5
01/03/2024 House Refer for Interim Study: MA VV 01/03/2024 HJ 1 P. 36
08/14/2024 House Full Committee Work Session: 09/12/2024 10:00 am LOB 302-304
09/25/2024 House Executive Session: 10/17/2024 10:00 am LOB 302-304
10/31/2024 House Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)